When is pharmacotherapy necessary for Tourette syndrome? The risks vs reward

Tourette syndrome is a neurodevelopmental disorder characterized by chronic motor and vocal tics. Both tic severity and co-morbid psychiatric disorders can affect patients' health-related quality of life to an extent that warrants active treatment interventions. Different decisional approaches can be implemented to determine the need for pharmacotherapy.

A critical appraisal of the existing literature on the clinical scenarios where pharmacotherapy for Tourette syndrome is deemed necessary has highlighted three indications: (1) physical discomfort - e.g. pain or injury; (2) emotional or social problems - e.g. depression or isolation; or (3) functional interference - e.g. impairment of academic achievements.

Pharmacotherapy for tic disorders aims to reduce tic severity enough to improve daily functioning and health-related quality of life rather than to eliminate symptoms. Expert consensus emphasizes patient-centered decision-making that integrates disease-specific quality of life measures with objective tic severity scales. Medications may be prioritized when tics cause significant impairment, pose medical risks, require rapid control, or coexist with treatable co-morbidities. Current guidelines rely largely on limited trials and expert opinion, with dopamine-modulating agents and alpha-2 agonists being most commonly used. Further research should focus on open questions about real-world effectiveness and generalizability of individual pharmacological agents.